Iovance Biotherapeutics Director Wayne Rothbaum disclosed the purchase of 10M shares at a price of $6.50. The $65M of shares were purchased on December 2. Rothbaum now owns 18,067,333 shares of Iovance, which is up 10% to $7.49 in after-hours trading following the disclosure in a regulatory filing.
previous post